Immunogenicity of the 9‐Valent Human Papillomavirus Vaccine in Occupationally‐Exposed Adults
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Objective: HPV is the most common sexually transmitted infection and has a well-established role in the pathogenesis of recurrent respiratory papillomatosis (RRP) and oropharyngeal squamous cell carcinoma (OPSCC). HPV DNA is detectable in surgical smoke, and case reports have linked occupational exposure to laryngeal papillomatosis in healthcare workers. In 2026 a joint European Laryngological Society/Union of European Phoniatricians Delphi consensus agreed that occupational exposure is plausible and that vaccination should be offered to workers at risk, but stronger recommendations were not issued due to absence of transmission and immunogenicity data. Immunogenicity data in adults over 26-particularly men-remain minimal in the literature. Methods: In a single-center prospective study, 9-valent HPV vaccine naïve operating room staff and surgeons within otolaryngology, general surgery, urology, and obstetrics-gynecology aged 27-69 were recruited to receive the standard three-dose 9-valent vaccine. Antibody titers for HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured at baseline (Month 0) and after the completion of their vaccine series (Month 7). Results: Of 33 enrolled adults, 21 completed the study (18 male, 3 female; mean age 36 years, range 27-61; 4 aged > 45 years). At Month 7, all 21 seroconverted for all nine types of HPV (100% seroconversion). Conclusion: The 9-valent HPV vaccine produced 100% seroconversion in a predominantly older, male, occupationally-exposed cohort that has been under-represented in prior research. This data suggests that offering vaccination to at-risk workers, addressing the immunogenicity gap identified by the ELS/UEP consensus. Level of Evidence: 3.
DOI: 10.1002/lio2.70626
Institutions: Eastern Virginia Medical School, Old Dominion University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,900
Funder: Merck
OpenAlex ID: W7225463496
